INM (InMed Pharmaceuticals Inc. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by INM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Daniel Schneeberger | 10%+ Owner | Buy | — | — |
| 2026-07-16 | Vivo Opportunity Cayman, LLC | 10%+ Owner | Buy | — | — |
| 2026-07-02 | Vivo Opportunity, LLC | 10%+ Owner | Buy | — | — |
| 2026-06-10 | Vivo Opportunity Cayman Fund, L.P. | 10%+ Owner | Buy | — | — |
| 2026-05-21 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | — | — |
| 2025-12-19 | Shane Aaron Johnson | Sr VP & General Manager | A | — | — |
| 2025-12-19 | Netta Jagpal | Chief Financial Officer | A | — | — |
| 2025-12-19 | ERIC A ADAMS | President & CEO | A | — | — |
| 2025-12-19 | MICHAEL WOUDENBERG | Chief Operating Officer | A | — | — |
| 2025-12-19 | Nicole Lemerond | Director | A | — | — |
| 2025-12-19 | Neil A Klompas | Director | A | — | — |
| 2025-12-19 | ANDREW HULL | Director | A | — | — |
| 2025-12-19 | ERIC C HSU | Sr. VP, Pre-Clinical Res/Dev | A | — | — |
| 2025-12-19 | John Steven Bathery | Director | A | — | — |
| 2025-12-17 | ERIC C HSU | Sr. VP, Pre-Clinical Res/Dev | H | — | — |
| 2025-12-17 | MICHAEL WOUDENBERG | Chief Operating Officer | H | — | — |
| 2025-12-17 | ERIC A ADAMS | President & CEO | H | — | — |
| 2025-12-17 | ANDREW HULL | Director | H | — | — |
| 2025-10-21 | Neil A Klompas | Director | A | — | — |
| 2025-02-03 | ANDREW HULL | Director | H | — | — |
| 2024-12-23 | Janet P Grove | Director | A | — | — |
| 2024-12-23 | Shane Aaron Johnson | Sr VP & General Manager | A | — | — |
| 2024-12-23 | ERIC C HSU | Sr. VP, Pre-Clinical Res/Dev | A | — | — |
| 2024-12-23 | Nicole Lemerond | Director | A | — | — |
| 2024-12-23 | ANDREW HULL | Director | A | — | — |
| 2024-12-23 | Bryan T Baldasare | Director | A | — | — |
| 2024-12-23 | MICHAEL WOUDENBERG | Chief Operating Officer | A | — | — |
| 2024-12-23 | Netta Jagpal | Chief Financial Officer | A | — | — |
| 2024-12-23 | ERIC A ADAMS | President & CEO | A | — | — |
| 2024-08-02 | ALEXANDRA DIANE JANET MANCINI | — | Sell | — | — |
| 2024-05-28 | ERIC C HSU | Sr. VP, Pre-Clinical Res/Dev | H | — | — |
| 2024-05-28 | ALEXANDRA DIANE JANET MANCINI | Sr VP, Clinical Reg Affairs | H | — | — |
| 2024-05-28 | MICHAEL WOUDENBERG | Chief Operating Officer | H | — | — |
| 2024-05-28 | ERIC A ADAMS | President & CEO | H | — | — |
| 2024-03-05 | ALEXANDRA DIANE JANET MANCINI | Sr VP, Clinical Reg Affairs | H | — | — |
| 2024-03-05 | ANDREW HULL | Director | H | — | — |
| 2024-03-05 | ERIC C HSU | Sr. VP, Pre-Clinical Res/Dev | H | — | — |
| 2024-02-22 | ANDREW HULL | Director | Buy | — | — |
| 2024-02-21 | ERIC A ADAMS | President & CEO | Buy | — | — |
| 2023-12-26 | Nicole Lemerond | Director | A | — | — |
| 2023-12-26 | ERIC C HSU | Sr. VP, Pre-Clinical Res/Dev | A | — | — |
| 2023-12-26 | Jonathan Tegge | Interim CFO | A | — | — |
| 2023-12-26 | ALEXANDRA DIANE JANET MANCINI | Sr VP, Clinical Reg Affairs | A | — | — |
| 2023-12-26 | MICHAEL WOUDENBERG | Chief Operating Officer | A | — | — |
| 2023-12-26 | Janet P Grove | Director | A | — | — |
| 2023-12-26 | Shane Aaron Johnson | Sr VP & General Manager | A | — | — |
| 2023-12-26 | ANDREW HULL | Director | A | — | — |
| 2023-12-26 | ERIC A ADAMS | President & CEO | A | — | — |
| 2023-12-26 | Bryan T Baldasare | Director | A | — | — |
| 2023-12-06 | MICHAEL WOUDENBERG | Chief Operating Officer | H | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 801,000 | — |
| — | 10%+ Owner | 729,277 | — |
| — | 10%+ Owner | 724,395 | — |
| — | 10%+ Owner | 638,960 | — |
| — | 10%+ Owner | 600,000 | — |
| — | President & CEO | 2,198 | — |
| — | Director | 1,913 | — |
| — | Sr VP & General Manager | 609 | — |
| — | CFO | 23 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INM quote page; the site-wide leaderboard is on the insider transactions hub.